{"id":"https://openalex.org/W3097057554","doi":"https://doi.org/10.1182/blood-2020-137265","title":"Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study","display_name":"Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study","publication_year":2020,"publication_date":"2020-11-05","ids":{"openalex":"https://openalex.org/W3097057554","doi":"https://doi.org/10.1182/blood-2020-137265","mag":"3097057554"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-137265","doi":"https://doi.org/10.1182/blood-2020-137265","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137265","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046772202","display_name":"Alessandro Maria Vannucchi","orcid":"https://orcid.org/0000-0001-5755-0730","observed_orcids":["https://orcid.org/0000-0001-5755-0730"]},"institutions":[{"id":"https://openalex.org/I4210115393","display_name":"Azienda Ospedaliero-Universitaria Careggi","ror":"https://ror.org/02crev113","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210115393"]},{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandro M. Vannucchi","raw_affiliation_strings":["Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy","institution_ids":["https://openalex.org/I4210115393","https://openalex.org/I45084792"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009381933","display_name":"Francesco Passamonti","orcid":"https://orcid.org/0000-0001-8068-5289","observed_orcids":["https://orcid.org/0000-0001-8068-5289"]},"institutions":[{"id":"https://openalex.org/I115752224","display_name":"University of Insubria","ror":"https://ror.org/00s409261","country_code":"IT","type":"education","lineage":["https://openalex.org/I115752224"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Passamonti","raw_affiliation_strings":["Department of Medicine and Surgery, University of Insubria, Varese, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine and Surgery, University of Insubria, Varese, Italy","institution_ids":["https://openalex.org/I115752224"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065098368","display_name":"Marina Kremyanskaya","orcid":"https://orcid.org/0000-0002-8912-3757","observed_orcids":["https://orcid.org/0000-0002-8912-3757"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marina Kremyanskaya","raw_affiliation_strings":["Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065621786","display_name":"Jason R. Gotlib","orcid":"https://orcid.org/0000-0001-8253-6156","observed_orcids":["https://orcid.org/0000-0001-8253-6156"]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Gotlib","raw_affiliation_strings":["Stanford Cancer Institute, Stanford, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford Cancer Institute, Stanford, CA","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057941081","display_name":"Jeanne M. Palmer","orcid":"https://orcid.org/0000-0002-2185-1504","observed_orcids":["https://orcid.org/0000-0002-2185-1504"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210127938","display_name":"Mayo Clinic Hospital","ror":"https://ror.org/03660jn93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099","https://openalex.org/I4210127938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeanne M. Palmer","raw_affiliation_strings":["Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210127938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036333273","display_name":"Kelly McCaul","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799572201","display_name":"Avera Health","ror":"https://ror.org/05nter171","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799572201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly McCaul","raw_affiliation_strings":["Avera Cancer Institute, Sioux Falls, SD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Avera Cancer Institute, Sioux Falls, SD","institution_ids":["https://openalex.org/I2799572201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032462496","display_name":"Vincent Ribrag","orcid":"https://orcid.org/0000-0002-5221-353X","observed_orcids":["https://orcid.org/0000-0002-5221-353X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Ribrag","raw_affiliation_strings":["Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025797543","display_name":"Adam J. Mead","orcid":"https://orcid.org/0000-0001-8522-1002","observed_orcids":["https://orcid.org/0000-0001-8522-1002"]},"institutions":[{"id":"https://openalex.org/I4210147381","display_name":"Oxford University Hospitals NHS Trust","ror":"https://ror.org/03h2bh287","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Adam J. Mead","raw_affiliation_strings":["Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom","institution_ids":["https://openalex.org/I4210147381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Harrison","raw_affiliation_strings":["Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4390039360","display_name":"Mays Cancer Center at UT Health San Antonio","ror":"https://ror.org/04aysmc18","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I165951966","https://openalex.org/I4390039360","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Mesa","raw_affiliation_strings":["Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX","institution_ids":["https://openalex.org/I4390039360"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008609620","display_name":"Jean\u2010Jacques Kiladjian","orcid":"https://orcid.org/0000-0002-8121-438X","observed_orcids":["https://orcid.org/0000-0002-8121-438X"]},"institutions":[{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Jacques Kiladjian","raw_affiliation_strings":["H\u00f4pital Saint-Louis et Universit\u00e9 Paris Diderot, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H\u00f4pital Saint-Louis et Universit\u00e9 Paris Diderot, Paris, France","institution_ids":["https://openalex.org/I4210144610","https://openalex.org/I4387154366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089433535","display_name":"Giovanni Barosi","orcid":"https://orcid.org/0000-0002-8357-7192","observed_orcids":["https://orcid.org/0000-0002-8357-7192"]},"institutions":[{"id":"https://openalex.org/I4210151645","display_name":"Policlinico San Matteo Fondazione","ror":"https://ror.org/05w1q1c88","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210151645","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giovanni Barosi","raw_affiliation_strings":["IRCCS Policlinico San Matteo Foundation, Pavia, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IRCCS Policlinico San Matteo Foundation, Pavia, Italy","institution_ids":["https://openalex.org/I4210151645"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056836936","display_name":"Torsten G. Gerike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Torsten G. Gerike","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050768804","display_name":"Jeevan K. Shetty","orcid":"https://orcid.org/0000-0001-9311-6675","observed_orcids":["https://orcid.org/0000-0001-9311-6675"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeevan K. Shetty","raw_affiliation_strings":["Celgene International S\u00e0rl, a Bristol-Myers Squibb Company, Boudry, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene International S\u00e0rl, a Bristol-Myers Squibb Company, Boudry, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070235123","display_name":"Joseph Pariseau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Pariseau","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060709384","display_name":"Gabriel Salgado Fernandes de Miranda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel Miranda","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003992164","display_name":"Martin Schwickart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Schwickart","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114104697","display_name":"Ana Carolina Giuseppi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana Carolina Giuseppi","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063436232","display_name":"Jennie Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennie Zhang","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063557220","display_name":"Jay T. Backstrom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112018","display_name":"Acceleron Pharma (United States)","ror":"https://ror.org/023annq56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112018"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay T. Backstrom","raw_affiliation_strings":["Acceleron Pharma, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acceleron Pharma, Cambridge, MA","institution_ids":["https://openalex.org/I4210112018"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":21,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":3.1928,"has_fulltext":false,"cited_by_count":30,"citation_normalized_percentile":{"value":0.93293769,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"47","last_page":"48"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/red-blood-cell-transfusion","display_name":"red blood cell transfusion","score":0.8799999952316284},{"id":"https://openalex.org/keywords/transfusion-burden","display_name":"transfusion burden","score":0.6449999809265137},{"id":"https://openalex.org/keywords/erythroid-maturation","display_name":"erythroid maturation","score":0.7480000257492065},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.8939999938011169},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.828000009059906},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.5699999928474426},{"id":"https://openalex.org/keywords/hypereosinophilia","display_name":"hypereosinophilia","score":0.41100001335144043}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8865221738815308},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.773820161819458},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.6467746496200562},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5050426125526428},{"id":"https://openalex.org/C2776557347","wikidata":"https://www.wikidata.org/wiki/Q37187","display_name":"Red blood cell","level":2,"score":0.44599416851997375},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.42886772751808167},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4260816276073456},{"id":"https://openalex.org/C2780014101","wikidata":"https://www.wikidata.org/wiki/Q183605","display_name":"Blood transfusion","level":2,"score":0.4176931381225586},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3243125081062317},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.2916761040687561},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2559443414211273}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-137265","doi":"https://doi.org/10.1182/blood-2020-137265","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-137265","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389233748","https://openalex.org/W4386332317","https://openalex.org/W4379339513","https://openalex.org/W4417007197","https://openalex.org/W2991379201","https://openalex.org/W4399203533","https://openalex.org/W4389259016","https://openalex.org/W4389259064","https://openalex.org/W4385665567","https://openalex.org/W2891695269"],"abstract_inverted_index":{"Introduction:":[0],"MF":[1,163],"is":[2,63,633],"a":[3,27,64,199,226,236,253,368,378,397,558,723],"clonal":[4],"stem":[5],"cell":[6],"disorder":[7],"characterized":[8],"by":[9],"progressive":[10],"bone":[11,685],"marrow":[12],"failure,":[13],"extramedullary":[14],"hematopoiesis,":[15],"and":[16,39,76,94,164,277,284,337,365,385,394,406,420,429,455,460,472,486,493,538,548,555,577,584,593,606,613,624,662,688,863],"debilitating":[17],"constitutional":[18],"symptoms.":[19],"Approximately":[20],"60%":[21],"of":[22,29,230,238,256,279,356,370,373,382,399,447,465,502,513,521,528,574,579,619,680,714,725,736,743,796,809,820,833,846,860,865,935,949,961,973,985,998,1010,1022,1034,1053,1173,1185,1198,1209],"pts":[23,31,81,135,155,161,217,265,280,293,423,489,551,609,638,643,681,693,703,717,726],"develop":[24],"anemia":[25,53,138,165],"within":[26,305,321],"year":[28],"diagnosis;":[30],"who":[32,615],"are":[33],"transfusion":[34,78,564],"dependent":[35],"have":[36,106],"worse":[37],"survival":[38],"quality-of-life":[40],"outcomes":[41],"(Tefferi":[42],"A,":[43],"et":[44,87,98,116,141],"al.":[45,88,99,117,142],"Mayo":[46],"Clin":[47],"Proc":[48],"2012;87:25-33).":[49],"Treatment":[50],"for":[51,188,204,210,235,261,292,300,330,335,377,635],"MF-associated":[52,137,719],"remains":[54],"critically":[55],"unaddressed,":[56],"with":[57,82,112,136,162,269,718,739,747],"no":[58,669],"approved":[59],"therapies":[60],"available.":[61],"Luspatercept":[62],"first-in-class":[65],"erythroid":[66],"maturation":[67],"agent":[68],"that":[69,317],"has":[70],"been":[71],"shown":[72],"to":[73,182,244,273,287,445,699],"increase":[74],"hemoglobin":[75],"reduce":[77],"burden":[79,565],"in":[80,134,154,195,222,266,281,341,362,391,426,452,490,506,535,543,552,562,581,597,610,677,716,1226,1235,1256,1265,1276,1286,1293],"myelodysplastic":[83],"syndromes":[84],"(Fenaux":[85,114],"P,":[86,115],"N":[89,100],"Engl":[90,101],"J":[91,102],"Med":[92,103],"2020;382:140-51)":[93],"\u03b2-thalassemia":[95],"(Cappellini":[96],"MD,":[97],"2020;382:1219-31).":[104],"Pts":[105,194,221,246,361,390],"also":[107],"achieved":[108,431,495,557,621,729],"multiple":[109],"response":[110,153,324,450,466,526,591,738],"episodes":[111,512,527],"luspatercept":[113,133,248,374,627,715,748],"Blood":[118,143],"2019;134:841).":[119],"We":[120],"previously":[121],"reported":[122,634],"findings":[123,710],"from":[124,349],"the":[125,189,306,322,331,415,439,480,503],"ongoing":[126,630],"open-label,":[127],"phase":[128],"2":[129,216,283,364,393,428,454,492,510,537,554,583,587,599,612],"ACE-536-MF-001":[130],"trial":[131],"evaluating":[132],"(Gerds":[139],"AT,":[140],"2019;134:557).":[144],"Here":[145],"we":[146],"report":[147],"updated":[148],"study":[149,862],"results,":[150],"focusing":[151],"on":[152,310,628,639,705,792,805,816,829,842,931,945,957,969,981,994,1006,1018,1030,1049,1169,1181,1194,1205],"requiring":[156,173],"RBC":[157,174,297,342,346,401,408,563],"transfusions.":[158],"Methods:":[159],"79":[160,637],"were":[166,172,315,328,353,653,668,682],"enrolled":[167],"(Figure).":[168,220],"Of":[169],"these,":[170,575],"43":[171],"transfusions,":[175],"defined":[176],"as":[177,313,355],"6-12":[178],"U/84":[179,186],"d":[180,187,251,403,410],"prior":[181,243],"treatment,":[183],"or":[184,798,811,822,835,848,937,951,963,975,987,1000,1012,1024,1036,1055,1175,1187,1200,1211],"4-12":[185],"3":[190,262,601],"expansion":[191,211,263],"cohort":[192,212,264],"pts.":[193],"Cohort":[196,215,223,267,536,544,598],"3B":[197,224,285,366,395,430,456,494,556,585,614],"received":[198,225,247,367,396],"stable":[200],"ruxolitinib":[201],"(RUX)":[202],"dose":[203,229,255],"\u2265":[205,301,338,497,515,524,559,567,589,678,695,733],"16":[206,701],"wks":[207,209,240,304,309,437,469,474,532,540,618],"(40":[208],"pts),":[213],"whereas":[214],"did":[218,318],"not":[219,319],"median":[227,237,369,379,398,463],"RUX":[228],"20":[231],"mg/d":[232],"(range":[233,241,375,404,411,470,475,533,541],"5-40)":[234],"73":[239],"29-359)":[242],"treatment.":[245,706],"every":[249],"21":[250],"at":[252],"starting":[254],"1.0":[257],"mg/kg":[258,260],"(1.33":[259],"3B),":[268],"doses":[270],"escalating":[271],"up":[272],"1.75":[274,288],"mg/kg;":[275],"81%":[276],"50%":[278,339,560],"Cohorts":[282,363,392,427,453,491,553,582,611],"escalated":[286],"mg/kg.":[289],"Primary":[290],"endpoint":[291],"receiving":[294,424,727],"transfusions":[295,343,425,728],"was":[296,457,467,530,749],"transfusion-independence":[298],"(RBC-TI)":[299],"12":[302,436,498,516,572],"consecutive":[303,435],"first":[307,440,448],"24":[308,383,441,617],"study.":[311,640],"However,":[312],"responses":[314],"observed":[316],"fall":[320],"24-wk":[323],"window,":[325],"additional":[326],"assessments":[327],"conducted":[329],"entire":[332,481],"treatment":[333,482,620],"duration":[334,381,464,520],"RBC-TI":[336,432,449,496,504,514,529,737],"decrease":[340],"(minimum":[344,566],"4":[345,568],"U":[347,569],"decrease)":[348],"baseline.":[350],"Intent-to-treat":[351],"data":[352],"analyzed":[354],"March":[357],"29,":[358],"2020.":[359],"Results:":[360],"8":[371,691],"cycles":[372],"1-39),":[376],"(mean)":[380],"(31)":[384],"23":[386],"(39)":[387],"wks,":[388,499],"respectively.":[389,413,477,500],"2.7":[400,407],"U/28":[402,409],"1-5)":[405],"2-4),":[412],"For":[414],"primary":[416],"endpoint,":[417],"2/21":[418],"(10%)":[419,692],"6/22":[421],"(27%)":[422,605],"over":[433,571],"any":[434],"during":[438],"wks.":[442,517],"Median":[443,518],"time":[444],"start":[446],"period":[451],"1.5":[458],"days":[459],"37":[461],"days;":[462],"49":[468],"16-82)":[471],"42":[473],"12-111),":[476],"When":[478],"assessing":[479],"period,":[483],"4/21":[484],"(19%)":[485],"8/22":[487],"(36%)":[488],"25%":[501],"responders":[505,580],"both":[507],"cohorts":[508],"experienced":[509,586,600],"separate":[511,588,602],"cumulative":[519],"all":[522,636],"individual":[523],"12-wk":[525,590,734],"59":[531],"24-82)":[534],"55":[539],"12-116)":[542],"3B.":[545],"8/21":[546],"(38%)":[547],"10/22":[549],"(46%)":[550],"reduction":[561],"reduction)":[570],"wks;":[573],"38%":[576],"20%":[578],"episodes,":[592],"1":[594,696],"pt":[595],"(13%)":[596],"responses.":[603],"4/15":[604],"8/14":[607],"(57%)":[608],"reached":[616],"clinical":[622],"benefit":[623],"therefore":[625],"continued":[626],"an":[629,793,806,817,830,843,932,946,958,970,982,995,1007,1019,1031,1050,1170,1182,1195,1206],"basis.":[631],"Safety":[632],"5":[641],"(6%)":[642],"had":[644,694],"grade":[645,744],"3-4":[646,745],"treatment-related":[647,670],"adverse":[648],"events":[649],"(AEs);":[650],"these":[651],"AEs":[652,673,746],"diarrhea":[654,689],"(n":[655,659,664],"=":[656,660,665],"2),":[657],"dehydration":[658],"1),":[661],"hypertension":[663,683],"3).":[666],"There":[667],"deaths.":[671],"Treatment-related":[672],"(any":[674],"grade)":[675],"occurring":[676],"5%":[679],"(13%),":[684],"pain":[686],"(9%),":[687],"(5%).":[690],"AE":[697],"leading":[698],"discontinuation.":[700],"(20%)":[702],"remain":[704],"Conclusions:":[707],"These":[708],"longer-term":[709],"suggest":[711],"durable":[712],"activity":[713],"anemia.":[720],"In":[721],"addition,":[722],"quarter":[724],"more":[730],"than":[731],"one":[732],"episode":[735],"luspatercept.":[740],"The":[741],"incidence":[742],"low.":[750],"Disclosures":[751],"Gerds:":[752],"Roche/Genentech:":[753],"Research":[754,758,762,769,772,780,784,788,870,874,879,884,888,892,897,902,906,909,925,1060,1069,1080,1113,1123,1143,1147,1150,1153,1156,1161,1165,1297,1300,1305,1308,1313,1317,1321,1324,1327],"Funding;":[755,759,763,770,773,781,785,871,875,880,885,893,898,903,907,926,1081,1144,1148,1151,1154,1157,1162,1298,1301,1306,1309,1314,1318,1322,1325,1328],"Celgene:":[756,1111],"Consultancy,":[757,768,779,883,895,900,928,1063,1074,1312,1320],"Sierra":[760,1108,1329],"Oncology:":[761,775,1109,1134],"AstraZeneca/MedImmune:":[764],"Consultancy;":[765,776,941,1083,1085,1135,1139,1141],"Incyte":[766,872,1095,1310],"Corporation:":[767,873,1096,1311],"Pfizer:":[771],"Apexx":[774],"CTI":[777,1102,1145,1302],"Biopharma:":[778,891],"Gilead":[782,1090],"Sciences:":[783,1091],"Imago":[786],"Biosciences:":[787],"Funding.":[789,889,910,1061,1166],"Vannucchi:Novartis:":[790],"Membership":[791,804,815,828,841,930,944,956,968,980,993,1005,1017,1029,1048,1168,1180,1193,1204],"entity's":[794,807,818,831,844,933,947,959,971,983,996,1008,1020,1032,1051,1171,1183,1196,1207],"Board":[795,808,819,832,845,934,948,960,972,984,997,1009,1021,1033,1052,1172,1184,1197,1208],"Directors":[797,810,821,834,847,936,950,962,974,986,999,1011,1023,1035,1054,1174,1186,1199,1210],"advisory":[799,812,823,836,849,938,952,964,976,988,1001,1013,1025,1037,1056,1176,1188,1201,1212],"committees,":[800,824,837,989],"Speakers":[801,825,838,852,855,912,916,919,922,1071,1093,1097,1100,1106,1115,1119,1125],"Bureau;":[802,826,839,853,856,913,917,920,1072,1094,1098,1101,1107,1116,1120,1126],"Blueprint:":[803],"committees;":[813,939,953,965,977,1002,1014,1026,1038,1057,1177,1189,1202],"AbbVie:":[814,1152],"Celgene/BMS:":[827,1073],"Incyte:":[840,899,921,1015,1142],"committees.":[850,1213],"Passamonti:Novartis:":[851],"BMS:":[854,908,966,1289],"Roche:":[857,904,1003,1299],"Other:":[858,1065,1076],"Support":[859],"parent":[861],"funding":[864],"editorial":[866],"support.":[867],"Kremyanskaya:Constellation":[868],"Pharmaceuticals:":[869,887,1129],"Bristol":[876,1158,1190],"Myers":[877,1159,1191,1215,1219,1239,1244,1249,1269],"Squibb:":[878,1160,1192,1216,1220,1240,1245,1250,1270],"Protagonist":[881],"Therapeutics:":[882,1164],"Astex":[886],"Gotlib:CTI":[890],"Kartos:":[894],"Honoraria,":[896,901,905,929,943,955,967,979,992,1004,1016,1028,1047,1064,1075,1092,1105,1112,1118,1122],"McCaul:BMS:":[911],"Seattle":[914],"Genetics:":[915],"Karyopharm:":[918],"Bureau.":[923],"Ribrag:argenX:":[924],"pharmamar:":[927],"servier:":[940],"nanostring:":[942],"gilead:":[954],"AZD:":[978],"Other;":[990],"Infinity:":[991],"MSD:":[1027],"gustave":[1039],"roussy":[1040],"comprehensive":[1041],"cancer":[1042],"center:":[1043],"Current":[1044,1221,1223,1230,1232,1241,1246,1251,1253,1260,1262,1271,1273,1281,1283,1290],"Employment;":[1045],"EPZ:":[1046],"epizyme":[1058],"(EPZ):":[1059],"Mead:Novartis:":[1062],"travel,":[1066,1077],"accommodations,":[1067,1078],"expenses,":[1068,1079],"Funding,":[1070,1114,1124],"Abbvie:":[1082],"CTI:":[1084],"Gilead:":[1086],"Consultancy.":[1087,1217],"Harrison:Roche:":[1088],"Honoraria;":[1089,1110,1130],"Janssen:":[1099],"Biopharma":[1103,1303],"Corp:":[1104,1304],"Shire:":[1117],"Novartis:":[1121,1140,1203,1319],"AOP":[1127,1178],"Orphan":[1128],"Promedior:":[1131,1155],"Honoraria.":[1132],"Mesa:Sierra":[1133],"LaJolla":[1136],"Pharmaceutical":[1137],"Company:":[1138],"BioPharma:":[1146],"Genentech:":[1149,1307],"Samus":[1163],"Kiladjian:AbbVie:":[1167],"Orphan:":[1179],"Barosi:Bristol":[1214],"Gerike:Bristol":[1218],"Employment,":[1222,1231,1252,1261,1272,1282],"equity":[1224,1233,1254,1263,1274,1284,1291],"holder":[1225,1234,1255,1264,1275,1285,1292],"publicly-traded":[1227,1236,1257,1266,1277,1287,1294],"company.":[1228,1237,1258,1267,1278,1295],"Shetty:BMS:":[1229],"Pariseau:Bristol":[1238],"Employment.":[1242,1247],"Miranda:Bristol":[1243],"Schwickart:Bristol":[1248],"Giuseppi:BMS:":[1259],"Zhang:Bristol":[1268],"Backstrom:Acceleron":[1279],"Pharma:":[1280,1316],"company;":[1288],"Verstovsek:AstraZeneca:":[1296],"NS":[1315],"PharmaEssentia:":[1323],"ItalPharma:":[1326],"Oncolo":[1330]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}